

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊 生 物 科 技 有 限 公 司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

**APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR
AND
CHANGE IN THE COMPOSITION OF BOARD COMMITTEES**

The board of directors (the “**Board**”) of Wai Chun Bio-Technology Limited (the “**Company**”) hereby announces the following:

(1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Ms. Hong Ting (“**Ms. Hong**”) has been appointed as an independent non-executive director of the Company with effect from 5 October 2022.

Ms. Hong, aged 36, obtained a Bachelor of Business degree from The Chinese University of Hong Kong in 2008. She is a fellow member of the Hong Kong Institute of Certified Public Accountants and a Certified Public Accountant (Practising) in Hong Kong. She worked for an international audit firm and has over 14 years of experience in accounting, auditing, taxation and financial consulting. She has experience in performing audits for listed entities and multinational corporations. She has also been actively handling the reporting of major transactions of clients such as initial public offerings projects, very substantial acquisition transactions, very substantial disposal transactions, and right issues. The industries of her clients include property development, manufacturing and retailing, natural resources mining and trading, generation of natural resources, generation and distribution of natural gases, generation and distribution of electricity and power, operation of wind farm, and media and entertainment services.

In addition, Ms. Hong is familiar with the financial reporting standards, listing rules and companies ordinance. She is experienced in merger and acquisition, initial public offerings procedures and requirements including the review of the internal controls and performing due diligence. Ms. Hong is currently the director and senior executive of three corporate practice firms of certified public accountants in Hong Kong, namely CL Partners CPA Limited, CCTH CPA Limited and TKG CPA Limited. Ms. Hong is also currently a non-executive director of Alco Holdings Limited, a company listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Ms. Hong has entered into a letter of appointment with the Company as an independent non-executive director of the Company for an initial term of two years commencing from 5 October 2022. Ms. Hong will hold office until the first general meeting of the Company after her appointment and will thereafter be subject to retirement by rotation and re-election in accordance with the provisions of the articles of association of the Company. Pursuant to the letter of appointment, Ms. Hong is entitled to receive a director's fee of HK\$120,000 per annum. Such fee was determined by the Board with reference to her qualifications, experience, duties and responsibilities with the Company, and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Ms. Hong (i) did not hold any position with the Company or other members of the Group; (ii) did not hold any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years preceding the date of this announcement and did not have any other major appointments and professional qualifications; (iii) did not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company; (iv) did not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (v) had no other information to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities (“**Listing Rules**”) on the Stock Exchange.

Save as disclosed above, there are no other matters that need to be brought to the attention of shareholders of the Company in relation to the appointment of Ms. Hong and there is no other information required to be disclosed pursuant to any of the requirements under Rule 13.51(2) of the Listing Rules.

Ms. Hong confirmed that she met the independence criteria as set out in Rule 3.13 of the Listing Rules.

(2) CHANGE IN THE COMPOSITION OF BOARD COMMITTEES

Ms. Hong has been appointed as a member and the chairman of the audit committee of the Company, and a member of each of the nomination committee and remuneration committee of the Company with effect from 5 October 2022.

Reference is made to the announcement of the Company dated 18 July 2022 in relation to, among others, the non-compliance with the requirements under Rules 3.10(1), 3.10(2), 3.10A and 3.21 of the Listing Rules. Following the appointment of Ms. Hong, the Company has complied with the requirements under Rules 3.10(1), 3.10(2), 3.10A and 3.21 of the Listing Rules.

The Board wishes to express its warmest welcome to Ms. Hong on her new appointment.

By Order of the Board
Wai Chun Bio-Technology Limited
Chan Cheuk Ho
Executive Director

Hong Kong, 5 October 2022

As at the date of this announcement, the Board consists of one executive Director, namely Mr. Chan Cheuk Ho and three independent non-executive Directors, namely Mr. Wan Bo, Mr. Hau Pak Man and Ms. Hong Ting.